Innovative Molecules Completes Phase 1 for Oral Adibelivir, Paving Way to Phase 2 Trials Innovative Molecules GmbH announces the successful completion of its Phase 1 program for oral adibelivir, a promising treatment for herpes infections, entering Phase 2.

Innovative Molecules Completes Phase 1 for Oral Adibelivir, Paving Way to Phase 2 Trials #Germany #Munich #Clinical_Trials #Adibelivir #Innovative_Molecules

Innovative Molecules Progresses to Phase 2 Trials for Oral Adibelivir After Successful Phase 1 Completion Innovative Molecules GmbH has successfully completed Phase 1 of their oral adibelivir program, moving forward to Phase 2 aimed at treating herpes infections effectively.

Innovative Molecules Progresses to Phase 2 Trials for Oral Adibelivir After Successful Phase 1 Completion #Germany #Munich #Adibelivir #Innovative_Molecules #HSV_Treatment

Alfasigma Partners with Innovative Molecules for Rare HSV Encephalitis Treatment Alfasigma has gained exclusive rights to parenteral adibelivir, enhancing treatment options for HSV encephalitis, a rare but severe condition.

Alfasigma Partners with Innovative Molecules for Rare HSV Encephalitis Treatment #Italy #Bologna #Alfasigma #Adibelivir #Innovative_Molecules

Innovative Molecules Concludes Enrollment in Phase 1b IM-250 Clinical Trial for Genital Herpes Innovative Molecules GmbH has successfully completed enrollment for its Phase 1b clinical trial of IM-250, a groundbreaking treatment for genital herpes. This trial is crucial in evaluating its safety and effectiveness.

Innovative Molecules Concludes Enrollment in Phase 1b IM-250 Clinical Trial for Genital Herpes #Germany #Munich #Innovative_Molecules #IM-250 #Genital_Herpes